Cynata Therapeutics (CYP) Stock Overview
Engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CYP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.34 |
| 52 Week High | AU$0.42 |
| 52 Week Low | AU$0.14 |
| Beta | 1.0 |
| 1 Month Change | -9.21% |
| 3 Month Change | 46.81% |
| 1 Year Change | 32.69% |
| 3 Year Change | 1.47% |
| 5 Year Change | -51.41% |
| Change since IPO | -11.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYP | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 9.5% | -1.2% | -2.5% |
| 1Y | 32.7% | -34.3% | 1.6% |
Return vs Industry: CYP exceeded the Australian Biotechs industry which returned -34.3% over the past year.
Return vs Market: CYP exceeded the Australian Market which returned 1.6% over the past year.
Price Volatility
| CYP volatility | |
|---|---|
| CYP Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CYP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: CYP's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs.
Cynata Therapeutics Limited Fundamentals Summary
| CYP fundamental statistics | |
|---|---|
| Market cap | AU$83.41m |
| Earnings (TTM) | -AU$9.39m |
| Revenue (TTM) | AU$1.89m |
Is CYP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYP income statement (TTM) | |
|---|---|
| Revenue | AU$1.89m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.89m |
| Other Expenses | AU$11.28m |
| Earnings | -AU$9.39m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 100.00% |
| Net Profit Margin | -498.14% |
| Debt/Equity Ratio | 0% |
How did CYP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 12:33 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cynata Therapeutics Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Kallos | MST Financial Services Pty Limited |
| Darren Vincent | Shaw and Partners Limited |
| Nicholas Lau | Taylor Collison Limited |